VD's Model Portfolio & Discussion Thread Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Vector1 who wrote (2148)	8/22/1997 8:11:00 PM
From: Andrew H	of 9719

Damn V1, it does look interesting but has had a big runup. Saw palmetto and St. John's wort? Isn't Rman the wort expert? Seriously St. John's wort is already a big seller in the US for depression. If they get FDA approvals for these nutricious supplements, do they have any special rights to sell them? I think not. But there is certainly a huge market for such supplements (including muslef)--the question is how will they capture a large share of the market? Think I read that Neurogen (or a company with a similar name) is seeking FDA approval for an Alzheimer's indication for DHEA (which I take daily, but not for Alzheimer's (:>) ). If FDA passes, would doctors write prescriptions for just Neurogen's or PharmaPrint's products? And would people be willing to spend significantly more on them or just go to Price Club like me and buy 250 Schiff DHEA for $9? What do you think?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next